Target Folate Receptor Alpha in Ovarian Cancer?
Sep 17, 2018
Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.
Ovarian Cancer
Targeting the Tumor Microenvironment May Aid in Treatment of Ovarian Cancer
Sep 17, 2018
Certain malignancies may possess a common and targetable matrix response, which affects disease pathogeneis, according to a study in Cancer Discovery.
What Underlies PARP Inhibitor Resistance in Ovarian Cancer?
Sep 14, 2018
New research examines the mechanisms underlying why most patients with high-grade serous ovarian cancer develop resistance to PARP inhibitors.
Novel Early Screening Tool for Ovarian Cancer
Sep 13, 2018
Optical coherence tomography and multispectral fluorescence imaging have demonstrated promising results in the early detection of ovarian cancer.
Building a Better Mouse Model for High-Grade Serous Carcinoma
Sep 13, 2018
Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer.
Population Testing to Prevent Gynecologic Cancers
Sep 12, 2018
Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.
Sorafenib Offers Survival Improvements in Ovarian Cancer
Aug 24, 2018
Sorafenib combined with topotecan and then continued as maintenance therapy offered a significant improvement in survival outcomes in women with platinum-resistant ovarian cancer.
Apatinib/Etoposide Promising in Platinum-Resistant Ovarian Cancer
Aug 22, 2018
Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.
Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points
Aug 15, 2018
The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
Might CAR-NK–Based Immunotherapy Be More Effective, Less Toxic?
Jul 31, 2018
A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell–based immunotherapies.
